Insider Selling: Natus Medical Inc (NASDAQ:BABY) VP Sells 3,000 Shares of Stock

Natus Medical Inc (NASDAQ:BABY) VP Dong Chune Christopher Chung sold 3,000 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $26.28, for a total value of $78,840.00. Following the sale, the vice president now owns 154,398 shares of the company’s stock, valued at $4,057,579.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Dong Chune Christopher Chung also recently made the following trade(s):

  • On Tuesday, May 21st, Dong Chune Christopher Chung sold 3,500 shares of Natus Medical stock. The shares were sold at an average price of $26.33, for a total value of $92,155.00.

Shares of Natus Medical stock opened at $24.65 on Thursday. The firm has a market capitalization of $835.86 million, a PE ratio of 17.36 and a beta of 0.58. The company has a quick ratio of 1.18, a current ratio of 1.70 and a debt-to-equity ratio of 0.18. Natus Medical Inc has a 12 month low of $23.58 and a 12 month high of $37.90.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Thursday, April 25th. The medical equipment provider reported $0.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.03. The business had revenue of $114.80 million during the quarter, compared to analysts’ expectations of $113.30 million. Natus Medical had a positive return on equity of 10.75% and a negative net margin of 8.62%. Natus Medical’s revenue was down 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.24 earnings per share. As a group, analysts predict that Natus Medical Inc will post 1.27 earnings per share for the current fiscal year.

BABY has been the subject of a number of analyst reports. BidaskClub raised Natus Medical from a “hold” rating to a “buy” rating in a report on Monday, May 20th. Zacks Investment Research downgraded Natus Medical from a “hold” rating to a “strong sell” rating in a report on Friday, February 15th. ValuEngine downgraded Natus Medical from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Finally, TheStreet downgraded Natus Medical from a “c-” rating to a “d+” rating in a report on Thursday, April 25th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Natus Medical presently has a consensus rating of “Hold” and an average target price of $36.00.

Institutional investors have recently bought and sold shares of the company. Pearl River Capital LLC acquired a new stake in Natus Medical during the fourth quarter valued at approximately $30,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Natus Medical during the first quarter valued at approximately $25,000. Royce & Associates LP boosted its holdings in Natus Medical by 55.4% during the first quarter. Royce & Associates LP now owns 1,100 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 392 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Natus Medical during the first quarter valued at approximately $38,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Natus Medical by 51.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,495 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 845 shares in the last quarter. Institutional investors and hedge funds own 91.59% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Riverton Roll and is the sole property of of Riverton Roll. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://rivertonroll.com/news/2019/06/13/natus-medical-inc-baby-vp-dong-chune-christopher-chung-sells-3000-shares.html.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.